SFTA2 and pancreatic adenocarcinoma: Also, we verified the clinical relevance of PMSRPS in the ICGC cohort and found that the expression of the risk gene SFTA2 was higher in patients with PAAD aged 65 years and younger than in patients older than 65 years (Figure 7K).